| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 14th December 2020 | David R Guyer | 9,270 | Open or private sale | $7.16 | $66,373.20 |
| 14th December 2020 | Keith Westby | 4,527 | Open or private sale | $7.16 | $32,413.32 |
| 12th December 2020 | David R Guyer | 17,200 | Exercise of derivative | $0.00 | |
| 12th December 2020 | Glenn Sblendorio | 22,950 | Exercise of derivative | $0.00 | |
| 12th December 2020 | David Francis Carroll | 12,500 | Exercise of derivative | $0.00 | |
| 12th December 2020 | Keith Westby | 12,500 | Exercise of derivative | $0.00 | |
| 10th December 2020 | David R Guyer | 9,602 | Open or private sale | $6.96 | $66,829.92 |
| 10th December 2020 | Keith Westby | 3,676 | Open or private sale | $6.96 | $25,584.96 |
| 9th December 2020 | David Francis Carroll | 10,000 | Exercise of derivative | $0.00 | |
| 9th December 2020 | Keith Westby | 10,000 | Exercise of derivative | $0.00 |
Iveric Bio
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
The company is developing novel therapeutics to treat diseases of the eye. The company is based in San Francisco and has offices in New York and London.
Ticker: OPHT
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1410939
Employees:
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $246 M (0%)
Assets, Current: $250 M (94%)
Property, Plant and Equipment, Net: $97 Th (-43%)
Other Assets, Noncurrent: $12 Th (0%)
Assets: $250 M (91%)
Liabilities, Current: $12 M (-8%)
Liabilities: $12 M (-8%)
Common Stock, Value, Issued: $89 Th (78%)
Common Stock, Shares, Issued: $89 M (80%)
Retained Earnings (Accumulated Deficit): $514 M (7%)
Stockholders' Equity (Parent): $238 M (0%)
Liabilities and Equity: $250 M (91%)
Research and Development: $13 M (-51%)
General and Administrative Expenses: $6 M (-44%)
Operating Income/Loss: $19 M (-49%)
Provision for income taxes: $386 Th (-3%)
News
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
